Bryan

Lau

,

PhD

My primary research area is in infectious disease epidemiology specifically related to HIV and SARS-CoV-2. Within HIV, I have primarily been focusing on HIV care continuum, risk of cancer, and the intersection of substance use (e.g., alcohol) with HIV clinical outcomes. With SARS-CoV-2 pandemic beginning in the US in 2020, much of my research focus has shifted to COVID-19 related research. This includes two randomized clinical trial of convalescent plasma among persons with high risk exposure to SARS-CoV-2 and individuals with mild ambulatory infections. Additionally, I am involved in a modeling study examining strategies for allocating convalescent plasma in the current setting of vaccine rollout. Finally, my colleagues and I have recently launched a study to examine how symptoms of COVID-19 evolve from the initial acute phase of infection to the post-acute stage including trying to understand who is and is not at risk for developing post-acute COVID-19 syndrome (a.k.a. long COVID-19).

My research interests also include epidemiological and statistical methods for cohort (both clinical and interval) studies and application of these methods. I have specific interest in developing new methods as well as adapting approaches from other fields as novel solutions to specific epidemiologic questions.

I am involved with multiple ongoing studies including the Johns Hopkins HIV Clinical Cohort Study, the CFAR Network of Integrated Clinical Systems (CNICS), Alcohol Research Consortium in HIV (ARCH), Medicaid Cancer (MediCan) Study, and am the director for the Biostatistics and Epidemiology Methodology Core of the Johns Hopkins CFAR.